Monopar Therapeutics Inc (MNPR)
EBITDA Growth
-116.56%
Quarterly · Period ending:
MNPR EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-116.56%period ending
Latest reported-116.56%period ending
MNPR Quarterly EBITDA YoY % (387.79% → -116.56%)
Year-over-year change
High-resolution chart · PNG
MNPR ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| -116.5577% | |
| -48.3082% | |
| 52.3981% | |
| -213.8192% | |
| -43.037% | |
| -59.9397% | |
| -11,240.2812% | |
| 33.2418% | |
| 22.0311% | |
| 32.5862% | |
| 674.6682% | |
| 18.5824% | |
| 20.3747% | |
| 0.9023% | |
| 2,311.4286% | |
| -415,983.3622% | |
| -32.8224% | |
| -29.6618% | |
| 100.035% | |
| -42.0752% | |
| -73.6873% | |
| 100% | |
| -7,128.2284% | |
| -5,707.7674% | |
| -353,134.6278% | |
| -1,584.5691% | |
| 5,110.2564% | |
| 870,400% | |
| 18.8462% | |
| -35,721% | |
| -408.6957% | |
| 93.0233% | |
| -69.0107% | |
| -110.2617% | |
| -102.4527% | |
| -125% | |
| 387.7907% |